Generated by AI
Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on precision oncology and biomarker-defined cancers. The company develops targeted cancer therapies designed to exploit DNA damage response and synthetic lethality pathways, aiming to address vulnerabilities in tumor cells while limiting impact on healthy tissue. Its current pipeline centers on investigational small-molecule programs, including APR-1051, a WEE1 kinase inhibitor, and ATRN-119, an ATR inhibitor, both being evaluated in clinical development for solid tumor indications. Aprea Therapeutics concentrates on oncology research and drug development for cancers with high unmet medical need, supporting its role in the broader market for targeted and precision medicine therapeutics. The company is headquartered in Doylestown, Pennsylvania.
Website3805 Old Easton Road
Doylestown, PA, 18902
United States
The latest articles about APRE.
Company to participate in 2026 Maxim Growth Summit (October 14) and Regional Biotechnology Conference (October 15)DOYLESTOWN, Pa., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers, today announced that Oren Gilad PhD, President and CEO, will participate in the 2026 Maxim Growth Summit,
Summary of Aug 26's posts. Generated by AI.
Summary of Feb 2's posts. Generated by AI.
Summary of Aug 13's posts. Generated by AI.
Summary of Aug 26's posts. Generated by AI.
Investors talking about APRE also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.